Related Experiment Videos
Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression
Niklas Klümper1, Isabella Syring2, Wenzel Vogel1
1Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Center for Medicine and Biosciences, Luebeck, Germany.
Frontiers in Medicine
|April 4, 2017
Summary
MED1 protein expression decreases as bladder cancer (BCa) progresses. Low MED1 levels correlate with muscle invasion, metastasis, and poorer survival, indicating its potential as a prognostic biomarker for BCa.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Bladder cancer (BCa) is a frequent malignancy with significant mortality.
- The Mediator complex regulates gene transcription and is implicated in various cancers.
- MED1's role in BCa is largely unexplored, despite its known functions in other cancers.
Purpose of the Study:
- To investigate MED1's role in bladder cancer.
- To evaluate MED1 as a prognostic biomarker for BCa.
- To assess MED1's utility as a biomarker for disease progression in BCa.
Main Methods:
- Immunohistochemistry (IHC) was used to assess MED1 protein expression.
- Tissue microarrays from 224 patients with benign urothelium and BCa (non-muscle invasive and muscle invasive) were analyzed.
- Quantitative image analysis was employed to evaluate MED1 expression levels.
Main Results:
- MED1 expression significantly decreased with BCa progression from benign to advanced stages.
- Low MED1 protein levels were associated with muscle invasion, lymph node positivity, and distant metastases.
- Patients with low MED1 expression exhibited significantly worse cancer-specific survival.
Conclusions:
- MED1 downregulation is linked to aggressive features of bladder cancer, including muscle invasion and metastasis.
- Decreased MED1 expression serves as a significant prognostic indicator for poorer survival in BCa patients.
- MED1 represents a potential biomarker for predicting disease progression and outcomes in bladder cancer.